Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis

OBJECTIVE: Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs, such as MTX, has demonstrated improvement in clinical outcomes in patients with RA. The primary objective of this post hoc analysis was to compare the efficacy of sarilumab (200 mg every 2 weeks) monotherapy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Bykerk, Vivian P, Buch, Maya H, Tanaka, Yoshiya, Kameda, Hideto, Praestgaard, Amy, van Hoogstraten, Hubert, Fernandez-Nebro, Antonio, Huizinga, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157062/
https://www.ncbi.nlm.nih.gov/pubmed/34508594
http://dx.doi.org/10.1093/rheumatology/keab676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157062/
https://www.ncbi.nlm.nih.gov/pubmed/34508594
http://dx.doi.org/10.1093/rheumatology/keab676

Ejemplares similares